文献速递白内障与屈光手术眼底病与葡萄膜炎

白内障术后玻璃体内抗生素类固醇注射联合局部非甾体抗炎药与三联滴眼液治疗的非感染性结局比较

Noninfectious Outcomes of Intravitreal Antibiotic Steroid Injection and Topical Nonsteroidal Antiinflammatory Drugs Versus Triple Drop Therapy After Cataract Surgery.
PubMed 文献 · Am J Ophthalmol · 2023-11-08

这项回顾性比较临床队列研究纳入美国3个中心2017至2022年间接受白内障手术的2143眼,比较玻璃体内抗生素类固醇(IVAS,莫西沙星-曲安奈德)注射联合术后局部非甾体抗炎药(NSAID)与标准三联滴眼液治疗(TDT)的非感染性结局。结果显示两组最佳矫正视力和眼压相似,IVAS-NSAID组术后并发症比例(6.5%)低于TDT组(11.6%,P < .001)。结论认为IVAS-NSAID方案可作为非飞秒激光辅助白内障手术及浅色虹膜患者局部方案的安全替代选择。

要点

  • IVAS-NSAID组术后并发症比例为6.5%,低于TDT组的11.6%(P < .001)。
  • 两组最佳矫正视力和眼压在所有时间点均相似。
  • 飞秒激光辅助白内障手术与IVAS-NSAID组持续性角膜水肿发生率升高相关。

核心结论

  • IVAS-NSAID方案总体术后结局与TDT方案相似且并发症更少。
  • IVAS-NSAID或可考虑作为非飞秒激光辅助白内障手术及浅色虹膜患者局部方案的安全替代选择。

研究设计与样本

  • 回顾性比较临床队列研究,纳入美国3个中心2017至2022年间接受白内障手术的2143眼(2143例患者),分为IVAS-NSAID组1079眼和TDT组1064眼。
  • 术前收集年龄、虹膜颜色、病史和眼部病史,术后1周、1个月和6个月记录最佳矫正视力、眼压及降眼压药物需求。

主要发现

  • IVAS-NSAID组与TDT组最佳矫正视力和眼压在全部时间点均相似。
  • TDT组11.6%眼出现术后并发症,IVAS-NSAID组为6.5%(P < .001)。
  • 飞秒激光辅助白内障手术与IVAS-NSAID组持续性角膜水肿发生率升高相关。
  • 深色虹膜眼在IVAS-NSAID组中黄斑囊样水肿、持续性角膜水肿和炎症反跳发生率更高。

关键数值与推荐

  • 主要结局指标为术后并发症,包括持续性前房炎症、持续性角膜水肿(PCE)、炎症反跳和黄斑囊样水肿。

临床怎么用

  • 作者认为IVAS-NSAID或可考虑作为非飞秒激光辅助白内障手术及浅色虹膜患者局部方案的安全替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare noninfectious outcomes of intravitreal antibiotic steroid (IVAS) injection (moxifloxacin-triamcinolone) and postoperative topical nonsteroidal antiinflammatory drugs (NSAID) with a standard 3-drop therapy (TDT) regimen (topical antibiotic, steroid, and NSAID) in patients after cataract surgery. DESIGN: Retrospective comparative clinical cohort study. METHODS: In 3 study centers in the United States, a total of 2143 eyes (N = 2143 patients) underwent cataract surgery with IVAS-NSAID or TDT between 2017 and 2022. Preoperative data were included, including patients' age, iris color, medical history, and ocular history. Postoperative data, including best-corrected visual acuity, intraocular pressure (IOP), and the need for IOP-lowering medications, were recorded at 1-week, 1-month, and 6-month time points. The primary outcome measures were postoperative complications, defined as persistent anterior chamber inflammation, persistent corneal edema (PCE), rebound inflammation, and cystoid macular edema, were compared between the 2 groups. RESULTS: There were 1079 eyes in the IVAS-NSAID group and 1064 eyes in the TDT group. Best-corrected visual acuity and IOP were similar between IVAS-NSAID and TDT eyes at all time points. A portion (11.6%) of TDT eyes experienced postoperative complications compared with 6.5% in IVAS-NSAID eyes (P < .001). Femtosecond laser-assisted cataract surgery was associated with increased rates of PCE in IVAS-NSAID eyes, and eyes with dark irides had a higher incidence of cystoid macular edema, PCE, and rebound inflammation in the IVAS-NSAID group. CONCLUSION: The IVAS-NSAID regimen overall had similar postoperative outcomes and fewer complications compared with the TDT regimen. IVAS-NSAID may be considered a safe alternative to topical regimens in non-femtosecond laser-assisted cataract surgery and patients with light irides.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mian OT, Asif H, Sandhu U, et al. Noninfectious Outcomes of Intravitreal Antibiotic Steroid Injection and Topical Nonsteroidal Antiinflammatory Drugs Versus Triple Drop Therapy After Cataract Surgery. Am J Ophthalmol. 2023. PMID: 37944685. doi:10.1016/j.ajo.2023.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。